戻る
Novelstem International Corp (NSTM) 収入
NSTM 株価推移チャート
NSTM 収入
Novelstem International Corp
$0.01
0%
$0
終値： Mar 27, 16:00:00 GMT-4
$0.01
0%
$0
アフターマーケット：Mar 27, 20:00:00 GMT-4
最新の利益結果: Q3 '25
報告済み: 2025-11-12
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
NSTMの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Novelstem International Corp NSTMの前四半期の収益はどうでしたか？
Novelstem International Corpの収益見積もりはいくらですか？
Novelstem International Corpの収益品質スコアはどれくらいですか？
Novelstem International Corpはいつ収益を報告しますか？
Novelstem International Corpの予想収益はいくらですか？
Novelstem International Corpは収益予想を上回りましたか？
主要データ
前終値
$0.01
始値
$0.01
当日レンジ
$0.01 - $0.01
52週レンジ
$0.01 - $0.04
取引高
20.0K
平均取引高
12.7K
配当利回り
--
1株当たり利益(TTM)
-0.00
時価総額
$468.8K
NSTMとは何ですか？
NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.